Mio-chol

Mio-chol Medicine

Overdose

No information provided.

Contraindications

Should not be used in those persons showing hypersensitivity to any of the components of this preparation.

Pharmaceutical form

Solution for intraocular administration

Undesirable effects

Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.

Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in

urinary bladder, and headache have been reported with topical or systemic application of carbachol.

The following additional reactions have been identified during post-approval use of Mio-Chol (carbachol intraocular solution, USP) in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to Mio-Chol, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.

Therapeutic indications

Intraocular use for obtaining miosis during surgery. In addition, Mio-Chol (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.

Name of the medicinal product

Mio-Chol

Qualitative and quantitative composition

Carbachol

Special warnings and precautions for use

WARNINGS

For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease.

The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.

PRECAUTIONS

Use only if the container is undamaged.

Carcinogenesis

Studies in animals to evaluate the carcinogenic potential have not been conducted.

Pregnancy

Category C. There are no adequate and well-controlled studies in pregnant women. Mio-Chol® (carbachol intraocular solution, USP) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.

Pediatric Use

Safety and efficacy in pediatric patients have not been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Dosage (Posology) and method of administration

Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.